A preclinical biotech company based in Wilmington, Delaware, focused on developing CAR‑T cell immunotherapies to treat severe allergic conditions. Founded in 2022, the company leverages novel CAR‑T ...

A clinical-stage biopharma company based in Shanghai, China, develoing novel antibody therapies targeting immune checkpoints and other tumor-related pathways. Founded in 2019, the company leverages ...

UK pharma major GSK reported better-than-expected second-quarter 2026 results, helped by continued growth in Specialty ...

ViiV Healthcare's two-drug HIV pill Dovato (dolutegravir/lamivudine) has matched the efficacy of Gilead's market-leading ...

US obesity specialist Ambrosia Biosciences has strengthened its clinical and scientific ranks, naming cardiometabolic drug ...

US biotech Apnimed has set the terms for its long-awaited initial public offering, seeking to raise up to $150 million as it prepares for a potential commercial launch of its lead obstructive sleep ...

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the ...

Borealis Bio emerged from stealth in August 2024 with $150 million in combined Series A financing from founding investor Versant Ventures and Novartis AG, as well as committed strategic research ...

A biotech company developing precision therapeutics that selectively eliminate pathogenic antibodies driving autoimmune and allergic diseases. Merida Biosciences is based in Cambridge, Massachusetts.

A life-sciences startup based in South San Francisco, focused on developing bispecific antibodies for immune and inflammatory diseases. Its discovery platform, DualScreen, enables screening of large ...

Positive high-level results from the CLARITY-Gastric01 global Phase III trial showed that sonesitatug vedotin (Sone-Ve) ...

Cambridge, USA-based biotech Oak Hill Bio this morning announced plans to go public via a combination with RA Capital-backed ...